Rayno Top Winners YTD 10/12/15
Fibrocell Science (FCSC) up 69%
Clovis Oncology (CLVS) up 61.6%
Regeneron (REGN) up 28.4%
Seattle Genetics (SGEN) up 21.3%
Gilead Sciences (GILD) up 5.6%
——
Rayno Top Losers YTD
Biogen Idec (BIIB) down 21.5%….down again today in pre-market
Abbvie (ABBV) down 14.6%
Alexion(ALXN) down 13.6%
GlycoMimetics (GLYC) down 4.6%
Vertex (VRTX) down 4.3%
Two stocks to watch when earnings hit are Biogen BIIB) and Gilead Sciences (GILD) both huge winners over five years but technically weak lately. Both should be watched for margins and pricing:
BIIB trades at P/S of 6, Forward PE of 14.87, PEG 1.14, P/FCF 19.27.
GILD trades at P/S of 5, Forward PE of 8.64, PEG 0.62, P/FCF 8.49.
————-
Top Five Winners YTD 9/10/15: Fibrocell Science (FCSC) up 127.8 %, Clovis Oncology (CLVS) up 86.18%, Ignyta (RXDX) up 56.48%, Albany Molecular (AMRI) up 30.16, Regeneron (REGN) up 29.49%.
—–
Prices Updated 10/12/15
| Company | Ticker | Original | Price $ | 5 Yr High | RaynoTotal | Price 9/10 | YTD 10/12 | Price 10/12 |
| Start | % Perform | % Perform | ||||||
| 8/12/2015 | ||||||||
| Abbvie | ABBV | 3/25/2014 | 51.7 | 70.76 | 33 | 59.58 | -14.6 | 55.9 |
| Alexion | ALXN* | 2/2/2009 | 17.5 | 203.3 | 994 | 186 | -13.6 | 159.9 |
| Alkermes | ALKS | 3/22/2013 | 23 | 75.17 | 191 | 69.67 | 1 | 59.1 |
| Albany Molec | AMRI | 2/10/2011 | 4.32 | 23.95 | 391 | 21.19 | 6.9 | 17.43 |
| Amgen | AMGN | 2/2/2009 | 55 | 173.6 | 210 | 153.1 | -3.3 | 154.4 |
| Array | ARRY | 5/26/2015 | 7.7 | 8.59 | -22 | 5.93 | 5 | 4.97 |
| Biogen | BIIB | 2/2/2009 | 48.5 | 480.18 | 552 | 312.62 | -21.5 | 266.27 |
| Clovis Oncology | CLVS | 1/13/2015 | 60 | 102.28 | 31.3 | 104.26 | 61.6 | 90.75 |
| Fibrocell Sci | FCSC | 6/11/2014 | 3.7 | 6.4 | 90.2 | 5.9 | 69 | 4.38 |
| Gilead Sciences | GILD* | 2/2/2009 | 25.5 | 123.37 | 356 | 107.25 | 5.6 | 99.6 |
| GlycoMimetics | GLYC | 10/16/2015 | 6.74 | 9.68 | 12.7 | 7.6 | -4.6 | 6.89 |
| Ignyta | RXDX | 4/7/2015 | 10 | 19.4 | 37.2 | 15.57 | 1 | 10.05 |
| Regeneron | REGN | 2/2/2009 | 17.5 | 544 | 3308 | 531.72 | 28.4 | 527 |
| Roche ADR | RHHBY* | 1/30/2014 | 33.5 | 38.54 | 9.5 | 33.29 | -3 | 33 |
| Seattle Gene | SGEN | 2/2/2009 | 9.5 | 49.84 | 471 | 41.58 | 21.3 | 38.9 |
| Vertex | VRTX | 11/15/2013 | 62.8 | 137.5 | 219 | 132 | -4.3 | 113.5 |
| *split | ||||||||
| Acquired | Acq Price | % Return | ||||||
| Astex | ASTX | 1.63 | 8.5 | 421 | ||||
| Cephalon | CEPH | 76.5 | 81.5 | 6.5 | ||||
| Cubist | CBST | 21.5 | 102 | 374 | ||||
| Optimer | OPTR | 11.8 | 10.75 | -9 | ||||
| PharmCyclics | PCYC | 38.2 | 261 | 583 | ||||
| ViroPharma | VPHM | 12 | 50 | 316 | ||||
| ETFs | P 8/12/15 | P10/12/15 | Perf %YTD | |||||
| FBT | 128.42 | 121 | 102.35 | flat | ||||
| IBB | 385.02 | 370 | 309.23 | 1.94 | ||||
| XBI | 261.6 | 236 | 64.17 (s) | 3.25 |
| Company | Ticker | Original Start | Price $ | 5 Yr High | Total % | Price 9/10 | YTD | |
| Perform. | % Perform | |||||||
| 8/12/15 | ||||||||
| Abbvie | ABBV | 3/25/2014 | 51.7 | 70.76 | 33 | 59.58 | -8.97 | |
| Alexion | ALXN* | 2/2/2009 | 17.5 | 203.3 | 994 | 171.65 | -7.23 | |
| Alkermes | ALKS | 3/22/2013 | 23 | 75.17 | 191 | 69.67 | 18.97 | |
| Albany Molec | AMRI | 2/10/2011 | 4.32 | 23.95 | 391 | 21.19 | 30.16 | |
| Amgen | AMGN | 2/2/2009 | 55 | 173.6 | 210 | 153,14 | -3.86 | |
| Array | ARRY | 5/26/2015 | 7.7 | 8.59 | -22 | 5.93 | 25.37 | |
| Biogen | BIIB | 2/2/2009 | 48.5 | 480.18 | 552 | 312.62 | -7.9 | |
| Celldex | CLDX | 8/20/2014 | 15 | 32.82 | 10.7 | 14.92 | -18.25 | |
| Clovis Oncology | CLVS | 1/13/2015 | 60 | 102.28 | 31.3 | 104.26 | 86.18 | |
| Fibrocell Sci | FCSC | 6/11/2014 | 3.7 | 6.4 | 90.2 | 5.9 | 127.8 | |
| Gilead Sciences | GILD* | 2/2/2009 | 25.5 | 123.37 | 356 | 107.25 | 13.78 | |
| GlycoMimetics | GLYC | 10/16/2015 | 6.74 | 9.68 | 12.7 | 7.6 | -2.64 | |
| Ignyta | RXDX | 4/7/2015 | 10 | 19.4 | 37.2 | 15.57 | 56.48 | |
| Regeneron | REGN | 2/2/2009 | 17.5 | 544 | 3308 | 531.72 | 29.49 | |
| Roche ADR | RHHBY* | 1/30/2014 | 33.5 | 38.54 | 9.5 | 33.29 | -2.09 | |
| Seattle Gene | SGEN | 2/2/2009 | 9.5 | 49.84 | 471 | 41.58 | 29.41 | |
| Vertex | VRTX | 11/15/2013 | 62.8 | 137.5 | 219 | 132 | 11.11 | |
| *split | ||||||||
| Acquired | Acq Price | % Return | ||||||
| Astex | ASTX | 1.63 | 8.5 | 421 | ||||
| Cephalon | CEPH | 76.5 | 81.5 | 6.5 | ||||
| Cubist | CBST | 21.5 | 102 | 374 | ||||
| Optimer | OPTR | 11.8 | 10.75 | -9 | ||||
| PharmCyclics | PCYC | 38.2 | 261 | 583 | ||||
| ViroPharma | VPHM | 12 | 50 | 316 | ||||
| ETFs | P 8/12/15 | Price 9/10 | Perf %YTD | |||||
| FBT | 128.42 | 121 | 115.38 | 13.1 | ||||
| IBB | 385.02 | 370 | 350.72 | 15.6 | ||||
| XBI | 261.6 | 236 | 228.67 | 22.64 | ||||
Updated 8/12/15
| Company | Ticker | Original Start | Price $ | 5 Yr High | RaynoTotal | Price 8/12 | YTD | |
| % Perform | % Perform | |||||||
| Abbvie | ABBV | 3/25/2014 | 51.7 | 70.76 | 33 | 68.76 | 5 | |
| Alexion | ALXN* | 2/2/2009 | 17.5 | 203.3 | 994 | 191 | 3.2 | |
| Alkermes | ALKS | 3/22/2013 | 23 | 75.17 | 191 | 67.88 | 15.9 | |
| Albany Molec | AMRI | 2/10/2011 | 4.32 | 23.95 | 391 | 21.23 | 30.4 | |
| Amgen | AMGN | 2/2/2009 | 55 | 173.6 | 210 | 170.6 | 7.11 | |
| Array | ARRY | 5/26/2015 | 7.7 | 8.59 | -22 | 6 | 26.8 | |
| Biogen | BIIB | 2/2/2009 | 48.5 | 480.18 | 552 | 316.73 | -6.7 | |
| Celldex | CLDX | 8/20/2014 | 15 | 32.82 | 10.7 | 16.61 | -9 | |
| Clovis Oncology | CLVS | 1/13/2015 | 60 | 102.28 | 31.3 | 78.81 | 41 | |
| Fibrocell Sci | FCSC | 6/11/2014 | 3.7 | 6.4 | 90.2 | 7.04 | 172 | |
| Gilead Sciences | GILD* | 2/2/2009 | 25.5 | 123.37 | 356 | 116.25 | 23.3 | |
| GlycoMimetics | GLYC | 10/16/2015 | 6.74 | 9.68 | 12.7 | 7.6 | 5.5 | |
| Ignyta | RXDX | 4/7/2015 | 10 | 19.4 | 37.2 | 13.72 | 37.9 | |
| Regeneron | REGN | 2/2/2009 | 17.5 | 544 | 3308 | 579 | 41.2 | |
| Roche ADR | RHHBY* | 1/30/2014 | 33.5 | 38.54 | 9.5 | 36.68 | 3.2 | |
| Seattle Gene | SGEN | 2/2/2009 | 9.5 | 49.84 | 471 | 44.79 | 39.4 | |
| Vertex | VRTX | 11/15/2013 | 62.8 | 137.5 | 219 | 137.6 | 15.9 | |
| *split | ||||||||
| Acquired | Acq Price | % Return | ||||||
| Astex | ASTX | 1.63 | 8.5 | 421 | ||||
| Cephalon | CEPH | 76.5 | 81.5 | 6.5 | ||||
| Cubist | CBST | 21.5 | 102 | 374 | ||||
| Optimer | OPTR | 11.8 | 10.75 | -9 | ||||
| PharmCyclics | PCYC | 38.2 | 261 | 583 | ||||
| ViroPharma | VPHM | 12 | 50 | 316 | ||||
| Perform | ||||||||
| ETFs | P 7/13 | % YTD | ||||||
| FBT | 128.42 | 125 | 22.7 | |||||
| IBB | 385.02 | 379 | 25 | |||||
| XBI | 261.6 | 259 | 39 | |||||
——–
7/13/15
The Biotech Bull Market Is Now in its Sixth Year Led By Biopharmaceuticals
Here is the current Rayno Biopharmaceutical Stock Portfolio as of 7/13 prices:
- Top winners since inception (2009) are: Regeneron (REGN), Alexion (ALXN) and Biogen (BIIB).
- Winners 2015 YTD are Fibrocell Sciences (FCSC) up 109%, Seattle Genetics (SGEN) up 47.7%, Celldex Therapeutics (CLDX) up 35.5%, Regeneron (REGN) up 30.7% and Gilead Sciences (GILD) up 21.5%.
- Six companies were acquired over five years: Astex, Cephalon, Cubist, Optimer, Pharmacyclics, and Viropharma.
- See previous posts on the Biotech Bull Market.
- Mid Cap biotechs should lead the market higher.
- All market trends in biotech are intact with healthcare sector leadership, M&A and revenue growth.
NOTE: forgot to add Ignyta (RXDX) to portfolio below. Added on 4/7 at price just under $10.
We will update the Rayno Diagnostics and Tools portfolios later this month. Top picks are Abaxis (ABAX), Cepheid (CPHD) and Illumina (ILMN).
| Company | Ticker | Original Start | Price $ | 5 Yr High | RaynoTotal | Price 7/13 | YTD | |
| % Perform | % Perform | |||||||
| Abbvie | ABBV | 3/25/2014 | 51.7 | 70.76 | 34.8 | 69.59 | 6.31 | |
| Achillion | ACHN | 3/4/2013 | 8.6 | 16.87 | 5.6 | 9.08 | -25.88 | |
| Alexion | ALXN* | 2/2/2009 | 17.5 | 203.3 | 1070 | 199.11 | 7.61 | |
| Alkermes | ALKS | 3/22/2013 | 23 | 75.17 | 74 | 65.05 | 11 | |
| Albany Molec | AMRI | 2/10/2011 | 4.32 | 23.95 | 355 | 19.65 | 20.7 | |
| Amgen | AMGN | 2/2/2009 | 55 | 173.6 | 183 | 155.76 | -2.22 | |
| Array | ARRY | 5/26/2015 | 7.7 | 8.59 | -9 | 6.97 | 47.36 | |
| Biogen | BIIB | 2/2/2009 | 48.5 | 480.18 | 705 | 391.23 | 15.25 | |
| Celldex | CLDX | 8/20/2014 | 15 | 32.82 | 64.8 | 24.73 | 35.5 | |
| Fibrocell Sci | FCSC | 6/11/2014 | 3.7 | 6.4 | 46.2 | 5.41 | 108.9 | |
| Gilead Sciences | GILD* | 2/2/2009 | 25.5 | 123.37 | 347 | 114.55 | 21.5 | |
| Regeneron | REGN | 2/2/2009 | 17.5 | 544 | 2965 | 536.21 | 30.7 | |
| Roche ADR | RHHBY* | 1/30/2014 | 33.5 | 38.54 | 9.4 | 36.68 | 7.9 | |
| Seattle Gene | SGEN | 2/2/2009 | 9.5 | 49.84 | 400 | 47.47 | 47.7 | |
| Vertex | VRTX | 11/15/2013 | 62.8 | 137.5 | 97 | 124.24 | 4.58 | |
| *split | ||||||||
| Acquired | Acq Price | % Return | ||||||
| Astex | ASTX | 1.63 | 8.5 | 421 | ||||
| Cephalon | CEPH | 76.5 | 81.5 | 6.5 | ||||
| Cubist | CBST | 21.5 | 102 | 374 | ||||
| Optimer | OPTR | 11.8 | 10.75 | -9 | ||||
| PharmCyclics | PCYC | 38.2 | 261 | 583 | ||||
| ViroPharma | VPHM | 12 | 50 | 316 | ||||
| Perform | ||||||||
| ETFs | P 7/13 | % YTD | ||||||
| FBT | 128.42 | 125 | 22.7 | |||||
| IBB | 385.02 | 379 | 25 | |||||
| XBI | 261.6 | 259 | 39 |